Prevention
|
|
|
|
Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers
J Am Coll Cardiol (2008) 51; 1742-8
H. Yasue, Y. Mizuno, E. Harada, T. Itoh, H. Nakagawa, M. Nakayama, H. Ogawa, S. Tayama, T. Honda, S. Hokimoto, S. Ohshima, Y. Hokamura, K. Kugiyama, M. Horie, M. Yoshimura, M. Harada, S. Uemura and Y. Saito |
|
The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy
J Am Coll Cardiol (2008) 52; 620-5
C. C. Wee, S. Girotra, A. R. Weinstein, M. A. Mittleman and K. J. Mukamal |
|
Simulation-based education improves quality of care during cardiac arrest team responses at an academic teaching hospital: a case-control study
Chest (2008) 133; 56-61
D. B. Wayne, A. Didwania, J. Feinglass, M. J. Fudala, J. H. Barsuk and W. C. McGaghie |
|
Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial)
Am J Cardiol (2008) 101; 1523-30
K. R. Tuttle, L. A. Shuler, D. P. Packard, J. E. Milton, K. B. Daratha, D. M. Bibus and R. A. Short |
|
Community-based provision of statin and aspirin after the detection of coronary artery calcium within a community-based screening cohort
J Am Coll Cardiol (2008) 51; 1337-41
A. J. Taylor, J. Bindeman, I. Feuerstein, T. Le, K. Bauer, C. Byrd, H. Wu and P. G. O'Malley |
|
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association
J Am Coll Cardiol (2009) 53; 298-304
J. S. Skyler, R. Bergenstal, R. O. Bonow, J. Buse, P. Deedwania, E. A. Gale, B. V. Howard, M. S. Kirkman, M. Kosiborod, P. Reaven and R. S. Sherwin |
|
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery
J Am Coll Cardiol (2008) 51; 1938-43
S. J. Shah, D. D. Waters, P. Barter, J. J. Kastelein, J. Shepherd, N. K. Wenger, D. A. DeMicco, A. Breazna and J. C. LaRosa |
|
Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women
J Am Coll Cardiol (2008) 51; 997-1002
R. Rossi, A. Nuzzo, G. Origliani and M. G. Modena |
|
Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study)
Circulation (2008) 117; 494-502
K. Mizuno, N. Nakaya, Y. Ohashi, N. Tajima, T. Kushiro, T. Teramoto, S. Uchiyama and H. Nakamura |
|
Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina
Heart (2008) 94; 1002-7
S. Miyamoto, M. Ueda, M. Ikemoto, T. Naruko, A. Itoh, S. Tamaki, R. Nohara, F. Terasaki, S. Sasayama and M. Fujita |
|
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients
J Am Coll Cardiol (2008) 52; 1769-81
E. J. Mills, B. Rachlis, P. Wu, P. J. Devereaux, P. Arora and D. Perri |
|
Impact of statin use on outcomes after coronary artery bypass graft surgery
Circulation (2008) 118; 1785-92
A. Kulik, M. A. Brookhart, R. Levin, M. Ruel, D. H. Solomon and N. K. Choudhry |
|
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Circulation (2008) 117; 3002-9
J. J. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, M. Szarek, J. C. LaRosa, T. R. Pedersen and S. M. Grundy |
|
The impact of prevention on reducing the burden of cardiovascular disease
Circulation (2008) 118; 576-85
R. Kahn, R. M. Robertson, R. Smith and D. Eddy |
|
Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India
Circulation (2009)
R. Joshi, C. K. Chow, P. K. Raju, R. Raju, K. S. Reddy, S. Macmahon, A. D. Lopez and B. Neal |
|
Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy
J Am Coll Cardiol (2008) 51; 2195; author reply 95-6
O. Iakoubova, J. Shepherd and F. Sacks |
|
Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention
Circulation (2009) 119; 902-7
W. S. Harris, D. Mozaffarian, E. Rimm, P. Kris-Etherton, L. L. Rudel, L. J. Appel, M. M. Engler, M. B. Engler and F. Sacks |
|
Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention
Circulation (2008) 117; 569-73; discussion 73
S. M. Grundy |
|
Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk
Circulation (2008) 117; 2875-83
J. P. Greving, E. Buskens, H. Koffijberg and A. Algra |
|
Defining a rational approach to screening for cardiovascular risk in asymptomatic patients
J Am Coll Cardiol (2008) 52; 330-2
P. Greenland and D. Lloyd-Jones |
|
Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry)
Am J Cardiol (2008) 102; 1002-8
C. Godino, S. Furuichi, A. Latib, N. Morici, A. Chieffo, E. Romagnoli, C. Tamburino, R. Barbagallo, M. Cera, D. Antoniucci, O. Goktekin, C. Di Mario, B. Reimers, E. Grube, F. Airoldi, G. M. Sangiorgi and A. Colombo |
|
Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors
J Am Coll Cardiol (2008) 51; 2040-4
C. Gazzaruso, S. B. Solerte, A. Pujia, A. Coppola, M. Vezzoli, F. Salvucci, C. Valenti, A. Giustina and A. Garzaniti |
|
The role of aspirin in cardiovascular prevention: implications of aspirin resistance
J Am Coll Cardiol (2008) 51; 1829-43
A. Y. Gasparyan, T. Watson and G. Y. Lip |
|
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study
J Am Coll Cardiol (2008) 52; 24-32
S. H. Choi, A. Chae, E. Miller, M. Messig, F. Ntanios, A. N. DeMaria, S. E. Nissen, J. L. Witztum and S. Tsimikas |
|
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
Circulation (2008) 117; 2458-66
C. M. Ballantyne, J. S. Raichlen, S. J. Nicholls, R. Erbel, J. C. Tardif, S. J. Brener, V. A. Cain and S. E. Nissen |
|
Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis
Circulation (2008) 117; 3109-17
R. Auer, J. Gaume, N. Rodondi, J. Cornuz and W. A. Ghali |
|
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial
J Am Coll Cardiol (2009) 53; 720-9
D. Atar, P. Petzelbauer, J. Schwitter, K. Huber, B. Rensing, J. D. Kasprzak, C. Butter, L. Grip, P. R. Hansen, T. Suselbeck, P. M. Clemmensen, M. Marin-Galiano, B. Geudelin and P. T. Buser |
|
In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention
J Am Coll Cardiol (2008) 51; 1539-42
J. A. Ambrose |
|
|
|
![](/image/summit/bttn_list.gif) |
|
|
|